Entity

Time filter

Source Type

Murviel-lès-Montpellier, France

Sizun G.,Idenix SARL an MSD Company since August 2014 | Pierra C.,Idenix SARL an MSD Company since August 2014 | Peyronnet J.,Idenix SARL an MSD Company since August 2014 | Badaroux E.,Idenix SARL an MSD Company since August 2014 | And 11 more authors.
Future Medicinal Chemistry | Year: 2015

Background: Ribonucleoside analogs possessing a β-methyl substituent at the 2′-position of the d-ribose moiety have been previously discovered to be potent and selective inhibitors of hepatitis C virus (HCV) replication, their triphosphates acting as alternative substrate inhibitors of the HCV RdRp NS5B. Results/methodology: In this article, the authors detail the synthesis, anti-HCV evaluation in cell-based replicon assays and structure-activity relationships of several phosphoramidate diester derivatives of 2′-C-methylguanosine (2′-MeG). Conclusion: The most promising compound, namely the O-[S-(hydroxyl)pivaloyl-2-thioethyl]{abbreviated as O-[(HO)tBuSATE)]} N-benzylamine phosphoramidate diester derivative (IDX184), was selected for further in vivo studies, and was the first clinical pronucleotide evaluated for the treatment of chronic hepatitis C up to Phase II trials. © 2015 Future Science Ltd. Source

Discover hidden collaborations